JPRN-jRCT2080220180未知Unknown
A long term study of SPP100 in patients with essential hypertension
ovartis Pharma K.K.0 个研究点目标入组 300 人开始时间: 2005年11月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Inclusion Criteria
- •- Male or female aged 20 to 80 years old
- •- Diagnosed as essential hypertension
- •Exclusion Criteria
- •- Patients with secondary hypertension or suspected of having secondary hypertension.
- •- Patients suspected of having malignant hypertension
- •- Patients with any serious diseases or symptoms
- •Other protocol-defined inclusion/exclusion criteria also apply
排除标准
- 未提供
研究者
相似试验
未知
3 期
ong-term Study of DSP-8153 in patients with essential hypertensioHypertensionJPRN-jRCT2080221238Dainippon Sumitomo Pharma Co., Ltd.
未知
3 期
SPP100 (Aliskiren) regimen in patients with severe hypertensioHypertensionJPRN-jRCT2080220236ovartis Pharma K.K.38
未知
3 期
A Phase 3 study of S-474474 in patients with essential hypertensioHypertensionJPRN-jRCT2080221505SHIONOGI & CO., LTD.
未知
3 期
A Long-Term Clinical Study of SFPP in Patients with OsteoarthritisOsteoarthritisJPRN-jRCT2080221798Taisho Pharmaceutical Co., LTD.200
已完成
1 期
A phase I study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatmentMalignant tumorsJPRN-UMIN000008485Kobe Haborland Immunotherapy Clinic9